|
RESEARCH PROGRAMS - American Lung Association of the Upper Midwest
Adequate Levels of Hydrogen Peroxide are Necessary to Macrophage Function
A. Brent Carter, M.D.
University of Iowa Hospitals and Clinics
Asbestosis, which is an important cause of pulmonary fibrosis, results from a high occupational exposure to asbestos (minimum fiber dose of 25-100 fibers/ml/year). Although standards regarding handling asbestos have changed, it is estimated that asbestos-associated deaths in the United States may exceed 200,000 by the year 2030. The initial defense-fighting cells in the lung are known as alveolar macrophages. The lungs of patients with asbestosis contain alveolar macrophages that spontaneously release inflammatory mediators, such as tumor necrosis factor-alpha (TNF-O), and reactive oxygen species, especially hydrogen peroxide (H2O2). In fact, asbestos fibers spontaneously catalyze the generation of reactive oxygen species, and studies have shown that proteins obtained from the lung of patients with asbestosis are oxidized. Studies also indicate that inhibition of TNF-O and H2O2 prevent the development of pulmonary fibrosis, which is a form of scarring in the lung. It is also clear that young macrophages that are newly recruited to the lung are primarily responsible for TNF-O production. We have found that adequate steady-state levels of H2O2 are necessary for TNF-O production. These levels of H2O2 are dependent on the activity of peroxide-generating enzymes, such as superoxide dismutase (SOD), and peroxide-removing enzymes, such as catalase and glutathione peroxidase. Thus, it appears that the balance between oxidant-producing enzymes and antioxidant enzymes regulates TNF-O production.
H2O2 is the most important reactive oxygen species involved in inducing inflammation in the lung. Asbestosis is a good disease model to explore the role of H2O2 in inducing inflammation because asbestos is still present in the environment and is known to induce high levels of H2O2. Although cells exposed to asbestos produce TNF-O and H2O2, the mechanism linking H2O2 generation to TNF-O production is not known. We have found that H2O2 is necessary for optimal production of TNF-O after exposure to asbestos and that the source of H2O2 is primarily from the peroxide-generating enzyme Cu,Zn-SOD. We have also found that alveolar macrophages from asbestosis patients have different enzymes that are activated, and these enzymes are known to be important for the development of inflammation. Our data demonstrates that H2O2 regulates the activation of these enzymes, which are known as mitogen-activated protein (MAP) kinases. Since the activity of these enzymes is often controlled by other proteins known as phosphatases, we have found that H2O2 regulates phosphatases that control the activity of MAP kinases. We also plan on comparing MAP kinase and Cu,Zn-SOD activity and H2O2 generation in alveolar macrophages obtained from asbestosis patients to alveolar macrophages obtained from normal volunteers. We have found that Cu,Zn-SOD activity and H2O2 generation is much greater in alveolar macrophages obtained from asbestosis patients than those obtained from normal volunteers. Although the studies in this proposal relate to asbestosis, they are novel studies that also provide important basic clues to understand the development of inflammation in the lung after exposure to an environmental agent.
Finding a Way to Help the Immune System Fight off Bacterial Infections After Influenza
Respiratory Dendritic Cells: Cell Migration and Induction of Adaptive Immunity During Virus Infections.
Kevin Legge, Ph.D.
University of Iowa Hospitals and Clinics
The lungs are routinely exposed to foreign pathogens such as bacteria and viruses in the air that we breathe. Often our immune system halts these pathogens before significant infections can occur. However when these pathogens do establish an infection, the immune system must kick in to fight it. In the lungs, respiratory dendritic cells (rDC) are thought to be responsible for inducing this immune system response. The researchers have found that following influenza infections, rDC rapidly migrate from the lungs to the lymph nodes and induce an immune response that is specific to influenza. But within 24 hours after influenza virus infection, rDC halt their migration. This halt is of particular concern following respiratory virus infections, where concurrent or new bacterial infections are common. The researchers will study the way in which rDC migration is stopped following influenza virus infections. They will then determine if manipulating this mechanism can restore rDC migration, thus helping the immune system fight off secondary infections. By boosting the immune system’s response to bacterial infections, complications ranging from otitis media and pneumonia in children to potentially deadly pneumonia in elderly adults might be avoided.
Gene-specific silencing for lung cancer therapy
Kounosuke Watabe, Ph.D.
Southern Illinois University
Lung cancer is the most prevalent malignancy worldwide. It has been estimated that 80% of lung cancer deaths among men and 75% of lung cancer deaths among women are attributable to smoking . The most important cause of the low cure rate in lung cancer is the high frequency of metastatic spread prior to diagnosis. Once metastases occur, patients cannot be cured by currently available therapies. Therefore, development of alternative treatment methods is urgently needed. Fatty acid synthase (FAS) has been found to be expressed specifically in a variety of tumors including lung cancer and hence considered to be an ideal target for chemotherapy. The goal of this project is to examine a possibility of using a small piece of RNA (called siRNA) which can "silence" the FAS gene as a therapeutic drug. In order to use this siRNA as a specific tumor drug, we will integrate this sequence into the adenovirus genome and administer this virus through inhalation to an animal model of lung cancer. We believe that the adenovirus containing siRNA to the fatty acid synthase gene specifically suppresses the expression of this gene and causes tumor cell death. If the result of the experiment is promising, we can eventually use this agent in a clinical trial. We believe that this unique design for the therapeutical approach to lung cancer will eventually yield an effective and non-toxic anti-cancer drug.
Improving the Treatment of Asthma
Malcolm Blumenthal, MD
University of Minnesota
ACRC Principal Investigator
The Asthma Clinical Research Centers (ACRC) Network, sponsored by the American Lung Association, conducts large clinical trials that provide vital information about caring for people who have asthma. The Network comprises 20 clinical centers and a data coordinating center, making it the largest of its kind. Its unique focus on large numbers of patients differentiates it from current federally funded and commercial research, and provides practical information about asthma care that has direct benefits for patients. The ACRC Network is currently conducting the following studies.
Improving the Treatment of Asthma
Lewis Smith, MD
Northwestern Center for Clinical Research
ACRC Principal Investigator
The Asthma Clinical Research Centers (ACRC) Network, sponsored by the American Lung Association, conducts large clinical trials that provide vital information about caring for people who have asthma. The Network comprises 20 clinical centers and a data coordinating center, making it the largest of its kind. Its unique focus on large numbers of patients differentiates it from current federally funded and commercial research, and provides practical information about asthma care that has direct benefits for patients. The ACRC Network is currently conducting the following studies.
Inhibiting Formation Of Bacterial Structures In Lungs Of Patients With Cystic Fibrosis
Timothy D. Starner, MD
University of Iowa, Iowa City, IA
Nontypeable Haemophilus Influenzae Biofilm Formation On Airway Epithelia. Nontypeable Haemophilus influenzae (NTHi) is one of the first bacteria to infect the lower airways of cystic fibrosis patients. NTHi infections may pave the way for other bacteria that cause extensive disease in cystic fibrosis. It has been shown in the lungs of cystic fibrosis patients that bacteria grow in a slime-like layer, called a biofilm. These biofilms are more resistant to antibiotics and to the body’s defenses. The researchers will study biofilm formation of NTHi. Understanding factors that can inhibit biofilm formation of NTHi may lead to new areas of research in cystic fibrosis or identify new targets for treatment.
Mechanism of Urokinase Plasminogen Activator Activation of Airway Eosinophil Function in Asthma
Julie Sedgwick, Ph.D.
University of Wisconsin-Madison
While a great deal has been learned about the mechanisms of asthma, there are still many poorly understood aspects of this lung disease. Eosinophils are potentially destructive cells that promote airway inflammation in asthma, but the mechanism by which they invade the airways of asthmatics and become activated has not been well defined. The researchers will look at how eosinophils are affected by substances called urokinase plasminogen activator receptors (uPAR), and study the role of increased eosinophils in the airways of people with allergic disease and asthma. This information will be critical to therapeutic strategies aimed at this cell.
Neutrophil-Endothelial Cell Interactions Elicited by S. pneumoniae in the Lung
Jessica G. Moreland, M.D.
University of Iowa Hospitals and Clinics
Streptococcus pneumoniae is the most common cause of bacterial pneumonia in both adults and children. This type of pneumonia can be very severe and may lead to bloodstream infection and death in a significant number of cases. One of the earliest events in our immune system’s response to pneumonia is the movement of white blood cells from the bloodstream to the lung. The principal long-term goal of this research project is to better understand some of the early events in the host response to bacterial pneumonia that initiate the movement of white blood cells from within the bloodstream to the lung, and may enhance the ability of the white blood cell to attack and kill the bacteria that is causing pneumonia. We have selected Streptococcus pneumoniae as the bacteria for our proposed studies for three reasons: 1) S. pneumoniae is the most common cause of bacterial pneumonia in adults and children, 2) this bacteria frequently exits the lung and moves into the bloodstream indicating that it directly contacts the endothelial cells or cells that line the blood vessels of the lung, and 3) pneumonia caused by this bacteria is characterized by large numbers of white blood cells moving from the bloodstream into the lung and causing severe inflammation .
Our specific focus involves investigation of the interaction of bacteria with both the human lung endothelial cells that line our blood vessels and human neutrophils. The overall hypothesis of this proposal is that Streptococcus pneumoniae elicits specific endothelial cell responses that directly participate in recruitment of white blood cells (neutrophils) from the vascular space to the lung during the onset of bacterial pneumonia. We propose that the white blood cells are activated by the process of migrating out of the bloodstream to the lung. To explore these questions, we plan to characterize the interaction between intact, live S. pneumoniae and pulmonary microvascular endothelial cells. Furthermore, we will define functional changes in the white blood cell (neutrophil) following migration across the endothelial cells that may enhance the ability of these white blood cells to destroy bacteria (e.g. S. pneumoniae) and/or surrounding host tissues. These questions are studied using a cell culture system to model events that occur in the body.
The Regulation of Myofibroblast Development and Apoptosis
Eun Jun Yun, Ph.D.
University of California
The purpose of this study is to address the role of myofibroblast development and death in distal lung morphogenesis. Distal airway (alveoli) formation is complex process requiring communication between various cells and its mechanism is largely unknown. Especially, the mechanisms that regulate myofibroblast development are not fully understood to date. Disrupted lung myofibroblast development and maintenance of alveolar structure may lead to pulmonary disorders such as bronchopulmonary dysplasia, fibrosis and emphysema. Therefore, it is important to understand the origin and development of this cell type to gain insights into both developmental and pathological processes. We believe that the growth factors that regulate compensatory growth will play a similar role in regulating alveolar septation in the newborn and will lead to new treatments for emphysema. Of note, the fate of tissue fibrosis is in part regulated via a balance between myofibroblast survivals vs. death. Our hypothesis is that balance between myofibroblast development and reducing its number is necessary for both alveolar septae formation in developing lungs and maintenance of alveoli structure in adult lungs. Based on results and findings from our previous studies, we hypothesized that the functions of growth factors HGF (Hepatocyte growth factor) and VEGF (Vascular endothelial growth factor) are closely associated in reciprocal interactions and probably regulate this balance.
We use genetically modified mice to study the function of these growth factors on myofibroblast development. Preliminary data show two interesting distinct phenotype with the loss of VEGF during postnatal period. If we decrease VEGF expression during early postnatal period, we find reduced number of myofibroblast and elastin. If we decrease VEGF expression during late postnatal period, we see lung destruction like emphysema. PECAM staining indicated abnormal distribution of pulmonary capillaries in the enlarged airways in these transgenic mice. We are currently examining for growth factors regulating these processes.
The results obtained from these studies will further our understanding of the mechanisms of lung formation and of the development of lung fibrosis and may provide novel targets for the development of new antifibrotic therapies.
|